Comparing 4 approaches for advanced solid tumors

Exclusion

• −Have known active central nervous system (CNS) metastases and/or leptomeningeal disease (LMD).
• −Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV.
• −Requirement for ongoing therapy with any prohibited medications.
• −Any prior allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation.
• −Have not recovered (ie, returned to Grade 1 or baselineBaselineYour starting measurements, taken before treatment begins.Read more →) from AEs due to a previously administered agent.
• −Diagnosis of immunodeficiency, either primary or acquired.
• −History of autoimmune disease or active autoimmune disease that has required systemic treatment within 2 years prior to the start of study treatment.
• −Have an active second malignancy.
• −Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.
• −Ascites or pleural effusion that is symptomatic and/or requiring medical intervention.
• −Meet any of the following criteria for cardiac disease: Myocardial infarction or unstable angina pectoris within 6 months of enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →. History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication). Mean QT interval corrected for heart rate using the Fridericia's formula (QTcF) ≥ 470 msec. New York Heart Association Class \> III congestive heart failure or known left ventricular ejection fraction \< 40%.
• −Live vaccines within 28 days of initiation of study drug(s).
• −Note: Other protocolProtocolThe detailed plan a study must follow.Read more → defined InclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more →/Exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → may apply.
• −Positive serum pregnancy test or participant who is breastfeeding.
• −Any anti-cancer therapy, whether investigational or approved within protocol specified time prior to initiation of study including: major surgery (\<4 weeks), experimental therapy (\<21 days or \<5 half-lives whichever is shorter), approved immunotherapy or biologic therapy (\<28 days), approved chemotherapy (\<21 days or \<42 days for mitomycin or nitrosoureas), approved targeted small molecule therapy (\<14 days or \<5 half-lives whichever is longer), hormonal therapy or other adjunctive therapy for cancers other than cancer under evaluation in this study (\<14 days) or radiation therapy (\<21 days).
• −History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or severe radiation pneumonitis (excluding localized radiation pneumonitis).